My name is Sigurður Ingur Kristinsson. I'm a haematologist at the University of Iceland and I am the PI for the iSTOP-MM study. My talk was termed What Have We Learned About the iSTOP-MM Study and basically I covered what we have published in recent years. So in short the iSTOP-MM Study stands for Iceland Screen Streets All Prevents Multiple Myeloma Back in 2016 we invited all Icelanders 40 years and older to join the screening study and 54% of the Icelandic population gave in for consent that it's more than 80,000 people. Since then we have screened more than 75,000 samples and identified approximately 5% of the Icelandic individuals have AMGUS. So then these individuals enter a randomized clinical trial with different kinds of follow-up and the overall aim of the study is to really understand if screening for AMGUS and myeloma is beneficial in terms of overall survival progression and so on. So what we have presented here at the meeting is firstly I think is important the prevalence of smoldering myeloma which was really not known before because you have to do a bone marrow biopsy or an aspiration to do that. So we identified that half a percent of 40 years and older have smoldering myeloma and this certainly has some implications when it comes to treating and follow-up of smoldering myeloma which is a very hot and interesting topic at the moment. Also we have identified the differences when it comes to progression. So if we actively screen and look for them and evaluate and work up and follow-up these individuals we will find more of more advanced disease. So screening compared to no screening we have identified more smoldering myeloma, more myeloma, more waldemström and smoldering waldemström and so on. There's really a clearance statistically a difference between these two entities. Also we can see that we really have changed the clinical phase of myeloma and by that I mean that if we are diagnosed with myeloma through screening we detect the disease one year earlier on average and we have less crap features and less acute presentations compared to those individuals that just turn up at the hospital with full-blown malignancy. Also we have identified and developed a model so you can use that to help you decide if you want to go ahead and do a bone marrow biopsy or aspiration in individual with MGUS. So basically it gives you an idea of what's the probability of finding smoldering myeloma or more than 10% plasma cells. Then you can use that in the clinic to help decide if you go ahead and do a biopsy or not. So these I think summarizes the main findings of the iStop MM study so far and obviously we will continue to do more research in the future.